References
- Bewick MA, Conlon MS, Lafrenie RM (2006). Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol, 24, 5645-51. https://doi.org/10.1200/JCO.2006.05.9923
- de las Penas R, Sanchez-Ronco M, Alberola V, et al (2006). Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol, 17, 668-75. https://doi.org/10.1093/annonc/mdj135
- Gurubhagavatula S, Liu G, Park S, et al (2004). XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol, 22, 2594-601. https://doi.org/10.1200/JCO.2004.08.067
- He J, Qiu LX, Wang MY, et al (2012). Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet, 131, 1235-44. https://doi.org/10.1007/s00439-012-1152-8
- Ichikawa W (2006). Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer, 9, 145-55. https://doi.org/10.1007/s10120-006-0373-8
- International Agency for Research on Cancer (2008). Globocan 2008: Stomach Cancer incidence, Mortality and Prevalence Worldwide in 2008. IARC.
- Isla D, Sarries C, Rosell R, et al (2004). Single nucleotide polymorphisms and outcome in docetaxel-cisplatintreated advanced non-small-cell lung cancer. Ann Oncol, 15, 1194-203. https://doi.org/10.1093/annonc/mdh319
- Keam B, Im SA, Han SW, et al (2008). Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms polymorphisms as a predictive and prognostic marker. BMC Cancer, 8, 148. https://doi.org/10.1186/1471-2407-8-148
- Kiyohara C, Yoshimasu K (2007). Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci, 4, 59-71.
- Liu YP, Ling Y, Zhang YP, et al (2011). Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy. Zhonghua Yi Xue Za Zhi, 91, 256-9.
- Ma H, Yu H, Liu Z, et al (2012). Polymorphisms of XPG/ERCC5 and risk of squamous cell carcinoma of the head and neck. Pharmacogenet Genomics, 22, 50-7. https://doi.org/10.1097/FPC.0b013e32834e3cf6
- Monzo M, Moreno I, Navarro A, et al (2007). Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fl uoropyrimidine.Oncology, 72, 364-70. https://doi.org/10.1159/000113534
- Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43. https://doi.org/10.1016/S1470-2045(01)00486-7
- Quintela-Fandino M, Hitt R, Medina PP, et al (2006). DNA repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatinbased induction chemotherapy. J Clin Oncol, 24, 4333-9. https://doi.org/10.1200/JCO.2006.05.8768
- Ruzzo A, Graziano F, Kawakami K, et al (2006). Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol, 24, 1883-91. https://doi.org/10.1200/JCO.2005.04.8322
- Saldivar JS, Lu KH, Liang D, et al (2007). Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol, 107, 223-9. https://doi.org/10.1016/j.ygyno.2007.06.006
- Weaver DA, Crawford EL, Warner KA, et al (2005). ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer, 4, 18. https://doi.org/10.1186/1476-4598-4-18
- Wohrer SS, Raderer M, Hejna M (2004). Palliative chemotherapy for advanced gastric cancer. Ann Oncol, 15, 1585-95. https://doi.org/10.1093/annonc/mdh422
- Wu X, Gu J, Wu TT, et al (2006). Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol, 24, 3789-98. https://doi.org/10.1200/JCO.2005.03.6640
- Yoon AJ, Kuo WH, Lin CW, et al (2011). Role of ERCC5 polymorphism in risk of hepatocellular carcinoma. Oncol Lett, 2, 911-4.
Cited by
- gene polymorphisms with susceptibility to gastric cancer in Chinese Han population vol.66, pp.10, 2014, https://doi.org/10.1111/jphp.12264
- Association between Polymorphisms in XRCC1 Gene and Treatment Outcomes of Patients with Advanced Gastric Cancer: A Systematic Review and Meta-Analysis vol.9, pp.1, 2014, https://doi.org/10.1371/journal.pone.0085357
- XRCC1 Gene Polymorphism, Clinicopathological Characteristics and Stomach Cancer Survival in Thailand vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6111
- Polymorphisms in Predicting Prognosis of Hepatocellular Carcinoma in Patients Receiving Transcatheter Arterial Chemoembolization vol.20, pp.4, 2016, https://doi.org/10.1089/gtmb.2015.0267
- Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy vol.34, pp.4, 2017, https://doi.org/10.1007/s12032-017-0923-4